[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"facet-joint-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:facet-joint-pain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100513156","offset-mechanisms-in-evaluation-of-lumbar-medial-branch-blocks-100513156",false,"NCT05961800","Offset Mechanisms in Evaluation of Lumbar Medial Branch Blocks","OMEGA Study: Offset Mechanisms in Evaluation of Lumbar Medial Branch Block","OMEGA","Inclusion Criteria:\n\n* Scheduled for lumbar MBB in UPMC Pain Management clinics\n* Age \\> 18 years old\n* Predominantly axial chronic low back pain at least 3 months on a daily basis\n* Must meet the minimum criteria for cognitive function using the PROMIS 2-item cognitive screener (\\>3)\n* Low back pain intensity of \\> 3\u002F10\n* Willing and able to receive study-related phone calls\n\nExclusion Criteria:\n\n* History of spine surgery at the level of the lumbar MBB\n* Active worker's compensation or litigation claims\n* New pain and\u002For psychiatric treatments within 2 weeks of enrollment\n* Not fluent in English and\u002For not able to complete the questionnaires\n* Any clinically unstable systemic illness that is judged to interfere with the study","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study examines the relationship between central nervous system (CNS) mechanisms of pain inhibition and the pain relief that occurs following a lumbar medial branch block (MBB).",[27,28,29,30],"Pain, Chronic","Facet Joint Pain","Pain, Procedural","Analgesia",[32,33,34,35,36,37],"lumbar","medial branch block","offset analgesia","onset hyperalgesia","QST","quantitative sensory testing","RECRUITING","2026-06-02",{"date":41,"type":42},"2026-06-04","ACTUAL",{"date":44,"type":42},"2023-07-05",{"date":46,"type":21},"2028-06",{"name":48,"class":49},"University of Pittsburgh","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":50},"100632942","phase-1-itx24-01-in-adult-male-and-female-patients-with-select-types-of-severe-chronic-neck--and-lower-back-pain-100632942","NCT07520240","ITX24-01 in Adult Male and Female Patients With Select Types of Severe Chronic Neck- and Lower Back Pain","A Sequential, Single Ascending Dose, Phase 1b, Randomised, Double-Blind, 2-Arm Study to Investigate the Safety and Tolerability of ITX24-01 Compared With Placebo In Adult Male and Female Patients With Select Types of Severe Chronic Neck- And Lower Back Pain","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet all the following criteria:\n\n1. Male or female. Women of childbearing potential must be willing to use contraceptives, or not be sexually active from the time when, during screening, pregnancy was excluded (by history and\u002For pregnancy test) until after the day of treatment has been completed (until ≥6 hours after administration of the IMP).\n2. Age ≥18 years\n3. Diagnosis of chronic zygapophysial joint neck- or lower back pain and elected to undergo medial branch neurotomy (MBN), aka radiofrequency ablation (RFA), as treatment for that pain syndrome. Participants can be patients who have undergone prior MBN (at the same level and side) and who have experienced pain recurrence and have, at the time of enrollment, opted for a repeat MBN procedure (at the same level and side). A positive MBB as determined by the Principal Investigator (PI) is required for all patients that was performed either at the time of the original diagnosis or at the time of pain recurrence. Thereby, for patients with a new diagnosis of chronic zygapophysial joint neck- or lower back pain (not treated with MBN in the past), a positive diagnostic MBB will be required. For patients with pain recurrence, a positive diagnostic MBB that was performed at the time of the original pain diagnosis, i.e., before the first MBN treatment, will be considered sufficient. (If no diagnostic MBB was performed at the time of the original diagnosis, a diagnostic MBB at the time of recurrence will be required.) The diagnosis will be reviewed by the Principal Investigator (PI) during Screening who will consider the timeline and diagnostic rigor of prior medical findings and tests in conjunction with the evaluation performed during screening (history and physical exam). PI agreement with the diagnosis (at their discretion) is required for the participant to meet this criterion.\n4. Ambulatory\n5. Body weight ≥48 kg\n6. Able to understand and comply with the study\n7. Willing to provide written informed consent\n8. Patients with zygapophysial joint neck- or lower back pain affecting a single joint (who require two injection of the IMP) are allowed in any group of the study (including Group 1). Patients with zygapophysial joint neck- or lower back pain affecting two joints at adjacent levels (who require three injection of the IMP) are allowed in Groups 2, 3 and 4 only.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Pregnant or breastfeeding\n2. Diagnosis of thoracic chronic zygapophysial joint pain\n3. Allergy or hypersensitivity to lidocaine, bupivacaine or iodinated radiographic contrast media\n4. Clinical history of angina, myocardial infarction or stroke experienced within the past year\n5. If taking warfarin, an INR ≥ 3.0\n6. Suicidal ideation or behavior (SIB)\n7. Pathological ECG. Exclude subjects with a marked baseline QTc prolongation defined as QTc \\>470 ms in males or \\>480 ms in females; or as QTc \\>450 ms in males or \\>470 ms in females with any additional torsades risk factors (heart failure, hypokalaemia, concomitant QT-prolonging drugs).\n8. Any other medical condition identified during screening that in the PI's judgement may preclude the safe performance of the study procedure\n9. For patients who are enrolled on the basis that they opt for repeat MBN procedure (at the same level and side), the prior MBN procedure must have been performed ≥6 months prior to enrollment.\n10. Zygapophysial joint neck- or lower back pain affecting- and requiring MBN of more than two joints or of more than one non-adjacent joint.",{"count":59,"type":21},32,[61],"PHASE1","The study is a single ascending dose (SAD), single-center, randomised, double-blind, placebo-controlled Phase 1b clinical trial designed to evaluate the safety, tolerability, and preliminary analgesic efficacy of ITX24-01 in patients with severe chronic zygapophysial joint pain (facet joint pain). The study consists of three dose escalation cohorts and one extension cohort.",[28],[65,66,67,68],"chronic zygapophysial joint pain","chronic zygapophyseal joint pain","back pain","neck pain","NOT_YET_RECRUITING","2026-04-06",{"date":72,"type":42},"2026-04-09",{"date":74,"type":21},"2026-06-01",{"date":76,"type":21},"2027-04-30",{"name":78,"class":79},"Interventional AnalgesiX Inc.","INDUSTRY",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":50},"100509152","phase-1-dose-escalation-pilot-study-to-evaluate-the-safety-of-alocyte-for-the-treatment-of-facetogenic-back-pain-100509152","NCT05909709","Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain","An Open Label Dose Escalation Pilot Study to Evaluate the Safety of Alocyte Delivered Via Intra-articular Facet Injection for the Treatment of Facetogenic Back Pain","Inclusion Criteria:\n\n* In order to be eligible to participate in this study, all individuals must meet all of the following criteria:\n\n  1. Subjects age \\> 18 years at the time of signing the Informed Consent Form.\n  2. Male or Female.\n  3. Ability of participant to understand and the willingness to sign a written informed consent document.\n  4. Facetogenic back pain diagnosed using the following diagnostic criteria Subjects who have chronic low back pain based on clinical evaluation. Pain onset at dorsal extension and release at flexion is often considered suggestive for facet pain, even if non-specific, such as maximal tenderness upon deep palpation of posterior elements.\n  5. Patient with up to 5 diseased facet joints\n  6. Chronic Facetogenic pain (≥ 6 months) in patients that have failed conservative management\n  7. Subjects must be reasonably able to return for multiple follow-up visits.\n  8. For Women of Child-Bearing Potential (WOCBP) only, willingness to use FDA-recommended birth control until 6 months post treatment.\n  9. Any male subject must agree to use contraceptives and not donate sperm during the study.\n\nExclusion Criteria:\n\n1. Previous surgical intervention for back pain\n2. Previous stem cell injection(s) within the last year\n3. Use of anticoagulation or NSAIDs within 5 days of the injection\n4. MRI finding of severe high-grade lumbar stenosis\n5. Leg pain exceeding back pain\n6. Pain worse with flexion maneuvers\n7. Fracture of lumbar vertebrae\n8. Inability to perform any of the assessments required for endpoint analysis.\n9. Clinically significant abnormal screening laboratory or clinical assessment values\n10. Use of medications during the early phase of treatment such as chronic narcotic use, systemic corticosteroid administration, local corticosteroid injection at facets anticoagulant therapy and viscosupplementation into facets, any investigational drug used within 3 months prior to screening or during study and surgery in the facets\n11. Subjects with serious co-morbidities are excluded.\n12. Evidence of inflammatory arthritis (example, rheumatoid arthritis and ankylosing spondylitis) or traumatic fractures, osteoarthritis, meniscoid entrapment, synovial impingement, joint subluxation, synovial inflammation, loss of cartilage, and mechanical injury.\n13. Have a clinical history of malignancy within 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), except curatively treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma, if recurrence occurs.\n14. Be currently participating (or participated within the previous 6 months) in an investigational therapeutic or device trial.\n15. Exhibiting signs of moderate or severe chronic respiratory disease (such as COPD, asthma, or pulmonary fibrosis).\n16. Patient with rheumatologic disorders.\n17. History of chronic liver disease or patient showing signs of clinical jaundice at the time of screening.\n18. History of severe chronic kidney disease or requiring dialysis.\n19. Patient with NYHA Class III or IV congestive heart failure or life-threatening arrhythmias.\n20. Subjects with a history of bleeding disorders, anticoagulation therapy that cannot be stopped as prior to the treatment.\n21. Any unstable condition of clinical significance, e.g., uncontrolled hypertension, unstable angina pectoris, worsening asthma.\n22. Hydroxychloroquine, oral or parenteral corticosteroids, immunosuppressants, or immunomodulating agents within 21 days prior to the Day 0\u002Ftreatment visit.\n23. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood pregnancy test at screening which will be within 72 hours of the IP infusion.\n24. Subject has a body mass index (BMI) greater than 42 kg\u002Fm2\n25. Subject has or had an active infection requiring systemic antibiotics within 12 weeks of enrollment in the study\n26. Inability to perform any of the assessments required for endpoint analysis.\n27. Active listing (or expected future listing) for transplant of any organ.\n28. Be a solid organ transplant recipient. This does not include prior cell-based therapy (\\>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.\n29. History of drug abuse (illegal \"street\" drugs except marijuana, if it is legal to use in states where patient resides), or prescription medications not being used appropriately for a pre-existing medical condition or alcohol abuse (≥ 5 drinks\u002Fday for ˃ 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months\n30. Patients with untreated HIV infection. However, patients can be enrolled if have been treated for HIV and the test negative for HIV viral load but still test positive for antibodies.",{"count":88,"type":21},15,[61],"The purpose of this study is to see if the use of Alocyte (cord blood plasma plus mononucleic cells) will be safe, well tolerated, and whether it causes any side effects. The study will also examine if the use of the Investigational Product (IP) is able to reduce local inflammation or alleviate Facetogenic back pain",[92,93,28],"Facet Joints; Degeneration","Back Pain",[95,96],"Back pain","Facet joint pain","2026-01-12",{"date":99,"type":42},"2026-01-13",{"date":101,"type":42},"2024-04-29",{"date":103,"type":21},"2026-10-01",{"name":105,"class":49},"Alimorad Farshchian"]